Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2024 to 2029

Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2024 to 2029

The eosinophilic esophagitis disease treatment market is evaluated at US$379.961 million for the year 2022 growing at a CAGR of 8.12% reaching the market size of US$656.118 million by the year 2029.

EoE (Eosinophilic esophagitis) is a disease of chronic type. Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis share symptoms such as chest pain and difficulty swallowing. It was considered a common disease in children for many years but has now grown in cases in young people that can be registered. Common symptoms of EOE are difficulty swallowing, pain in the chest cavity and upper abdomen, and vomiting.

The condition of eosinophilic Esophagitis occurs when the esophagus is filled with white blood cells, which are also known as eosinophils. These eosinophils should remain inside the digestive tract if they build up elsewhere, creating discomfort and inflammation inside the organ.

The market for eosinophilic esophagitis disease treatment is expected to be pushed by the rising prevalence of type II inflammatory illnesses, such as EoE, advancements in treatment approaches, and fierce competition among competitors for the first FDA-approved medicine to gain a first-mover advantage. EoE has a lot of needs, which is helping the eosinophilic esophagitis medication sector flourish. EoE diagnosis criteria are flawed since they are reliant on professional opinions (agreement among gastroenterologists, allergists, and pathologists) rather than evidence. Because there is no correlation between disease activity and patient symptoms, histologic criteria for EoE are currently unclear, and repeated tissue testing is required to confirm disease initiation.

The following are the symptoms of Eosinophilic Esophagitis in adults and children: In adults, symptoms are the backflow of undigested food, chest pain while chewing food that gets stuck in the esophagus, and difficulty in chewing and swallowing the food. In a child, some symptoms are common, like difficulty swallowing, and food getting stuck in the esophagus, while other symptoms in the child are vomiting, abdominal pain, difficulty eating, and no response to the medication.

MARKET DRIVER:

Increasing awareness campaigns for eosinophil-associated illnesses will bolster the growth of the market.

Various public and medical awareness programs have been designed and implemented to educate the public and medical community about eosinophil-related illnesses, which is expected to fuel market expansion. The market for eosinophilic esophagitis is being driven by an increase in the occurrences of digestive tract inflammatory illnesses. Eosinophilic esophagitis (EoE) market growth is expected to be boosted by increased allergies in the esophagus, eosinophil build-up, dysphagia, and impaction in the esophagus.
Regulatory support with timely and expedited approvals is expected to surge the market growth.

Regulatory support and expedited approvals can significantly boost the Eosinophilic Esophagitis (EoE) disease treatment market. This includes faster drug development, faster market access, encouraging investment, designation programs like Fast Track and Breakthrough Therapy, and flexibility in clinical trial design. Regulatory agencies also provide special considerations for rare diseases, streamline regulatory pathways, and encourage innovation. These factors contribute to the growth of the EoE treatment market, addressing unmet medical needs, providing life-improving or life-saving treatments, and fostering innovation in the development of novel treatment modalities.

MARKET RESTRAINTS:

Lack of disease awareness and treatment acceptability could hamper the market growth

The global eosinophilic esophagitis (EoE) market may be hampered by a lack of disease awareness and the acceptability of treatment for a given location. For the time being, no specific treatment for eosinophilic esophagitis has been approved. Obtaining regulatory approval for the drug is time-consuming and difficult, as regulatory agencies such as the US Food and Drug Administration (FDA) place significant and stringent restrictions on organizations involved in the clinical development, manufacture, marketing, and distribution of drugs.

North America is expected to dominate the Eosinophilic Esophagitis Treatment Market.

With the rising demand for asthma risk-reducing medications and high-end medical treatments, it is predicted that North America will have the biggest market volume in the Eosinophilic Esophagitis Treatment Market. Because of the increased occurrence of allergies that cause eosinophilic illnesses, Europe is expected to be the second-largest market for eosinophilic esophagitis (EoE). Due to growing awareness and the existence of generic companies, Asia-Pacific is likely to account for the biggest market share in the eosinophilic esophagitis (EoE) market in the forecasted period.

However, in places such as the Middle East, Africa, and South America, high therapeutic costs and a lack of patient information are limiting the eosinophilic esophagitis market.

Key development
September 2023- The FDA has approved Dupixent® (dupilumab) for Priority Review to treat children aged 1-11 with eosinophilic esophagitis (EoE). Dupixent is the first and only treatment in the U.S. approved for children and adults aged 12 and older with EoE, weighing at least 40kg. If approved, it would be the first and only treatment indicated in the U.S. for children aged 1-11.
May 2022- The FDA has approved Dupixent (dupilumab) as the first treatment for Eosinophilic Esophagitis (EoE), a chronic immune disorder affecting adults and pediatric patients aged 12 and above. EoE is a chronic inflammatory disorder characterized by difficulty swallowing, eating, and food sticking in the esophagus. Dupixent is a monoclonal antibody that inhibits part of the inflammatory pathway, making it the first FDA approval for a treatment for EoE.

Segmentation
By Product Type
Off-Label Drugs
Budesonide Oral Suspension
Fluticasone ODT
Mepolizumab
Reslizumab
Benralizumab
Dupilunab
Omalizumab
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Indonesia
Others